Drug class
Recombinant C1 esterase inhibitor; complement and contact-system pathway regulator
Mechanism of action
Recombinant human C1 esterase inhibitor suppresses plasma kallikrein and activated factor XII, reducing bradykinin formation and vascular permeability in hereditary angioedema.
General use cases
- Treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents under the US RUCONEST indication; not for routine prophylaxis and requires product-specific hypersensitivity precautions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
